在接受胰腺支架的高风险患者中,印米他辛不会减少ERCP后胰腺炎
Bingqing Bai1, Shaofei Wang1,2, Yemei Du1,3
1Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, China.
Digestive diseases and sciences
|July 15, 2024
概括
在已经接受胰腺支架的高风险患者中,直肠印米他不会进一步降低ERCP后胰腺炎 (PEP). 仅仅在胰腺支架上添加印米他辛并没有显示出预防PEP的显著益处.
科学领域:
- 胃肠病学 胃肠病学
- 内镜手术 进行内镜手术
- 胰腺疾病 胰腺疾病
背景情况:
- 直肠印米他用于预防ERCP后的胰腺炎 (PEP).
- 在接受预防性胰腺支架的患者中,其额外的益处尚不清楚.
- 这项研究评估了印米他辛在接受胰腺支架的高风险患者的影响.
研究的目的:
- 评估直肠印梅他辛在预防ERCP后胰腺炎 (PEP) 的疗效.
- 在高风险患者中,确定印梅他辛与预防性胰腺支架结合时是否提供额外的益处.
主要方法:
- 一项队列研究比较了接受印米他辛加胰腺支架与单独接受胰腺支架的患者.
- 这项研究包括高风险的患者,他们接受了具有挑战性的胆道管.
- 分析的结果包括PEP率,高血糖血症,出血和住院.
主要成果:
- 在印美他加支架组 (140名患者) 和单独支架组 (467名患者) 之间,整体PEP率没有显著差异.
- 在轻度,中度或重度PEP,高胺血症,胃肠道出血或术后住院期间没有统计学上显著的差异.
- 敏感性分析证实了这些发现.
结论:
- 在接受预防性胰腺支架的高风险患者中,直肠印米他并没有降低PEP的发生率或严重程度.
- 在胰腺支架上常规添加直肠印米他辛是不必要的,以减轻PEP.
相关概念视频
Endoscopic Procedures V: ERCP
170
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...
Patient...
170
Chronic Pancreatitis II: Collaborative Care
84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
84
Acute Pancreatitis II: Clinical Manifestations and Management
118
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
118
Chronic Pancreatitis I: Introduction
86
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
86
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
395
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
395
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166


